Innovation in Drug Delivery & Portfolio Renovation with Sofgen Pharmaceuticals

The Pharma industry is expected to reach $1.9Tn in revenue by 2027, increasing at a rate of 3-6% per year, according to IQVIA1, with some regions being driven by volume, and others by innovation. Growth in developed economies is projected to be slow, while other regions such as Latin America, Eastern Europe and parts of Asia are expected to have a strong growth. As the pharmaceutical industry continues to evolve, CDMOs will play an increasingly important role in drug development and manufacturing.
Leading pharmaceutical Softgel CDMO, Sofgen Pharmaceuticals, part of Procaps Group, is ideally placed to capitalize on this and other changing demands within the market through its range of Softigel technologies that service different patient and consumer needs and its new Softgel facility in the US.
As Latin America´s largest Softgel CDMO, Sofgen by Procaps Group offers contract manufacturing and development services in Softgel advanced technologies for pharmaceutical companies looking for differentiation, while simultaneously improving efficiency, and gaining access to specialized expertise, and unique technologies for fixed-dose combinations in Softgels, as an example.
Our Softgel facility and Center for Pharmaceutical Excellence located in West Palm Beach, US, specializes in the development and manufacturing of high-end softgel technologies, with expertise in complex oral modalities such as hormonal products and high potency compounds, and other differentiated manufacturing technologies.
Sofgen offers a diverse service portfolio that goes from Research for Advanced Delivery Technologies, End-to-end solutions for Orphan / Fast-track developments, pre-clinical and clinical developments for new Molecular Entities, lab analytical services, all the way to bottling & product inspection services.
Our expansion to the United States provides us with a wider capability to deliver our pharmaceutical products to our strategic partners and ensure the continued quality of their brands which are their most valued assets. The increase in production capacities will provide us with the opportunity to deliver a wider product array as we move even closer to our customers in the North American markets as we implement our ambitious growth plans.
The pharmaceutical industry is moving towards personalized medicine, which involves developing drugs tailored to specific patient needs. CDMOs are also increasingly focused on providing customized drug development and manufacturing services to meet the specific needs of their clients. Sofgen Pharmaceuticals, as an integrated CDMO, iCDMO, is investing in investigating what are these specific needs, so we can integrate our advanced oral technologies and services to tackle in a more direct and specific way those needs.
Through our innovative technologies for oral delivery systems, plus our vast knowledge and expertise of more than 45 years in Softgel development and manufacturing, we offer the flexibility, value, and customization of our partners´ needs, driven by our passion to develop customized products that exceed our customers’ expectations, with a relationship model based on connectivity, trust, and empathy.
Sofgen Pharmaceuticals, your flexible partner for Innovation in Softgel delivery.
[1] IQVIA. Global Use of Medicines 2023 Outlook to 2027. Jan 2023.

Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance